Panaxia Labs Israel, Ltd., Israel’s leading medical cannabis products manufacturer and Leriva Group, one of Greece’s leading distributors of medical equipment, medical supplies, and health services, announced a binding agreement of manufacture, commercialization, and distribution of medical cannabis finished products, developed by Panaxia for medical cannabis patients in Greece. Under the agreement, Panaxia will be responsible for registering the products, while complying with the European standard requirements, including EU-GMP; developing and manufacturing new and advanced products, including tablets, suppositories (candles), and inhalation products. Leriva, whose clients include physicians, hospitals, and pharmacies, will market, sell, and distribute Panaxia’s premium products under the Panaxir brand to patients, following a doctor’s prescription for labeling prevention and treatment of nausea as a result of taking Anti-Neoplastic drugs; Neuropathic Pain and Cancerous Pain and Spasticity caused by Multiple Sclerosis.

Sean Hocking, Cannabis Law Report, 05/20/2021 01:38:00

Open article: